Fundsmith LLP Trims Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Fundsmith LLP trimmed its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,662,855 shares of the company’s stock after selling 1,307 shares during the quarter. IDEXX Laboratories accounts for approximately 4.7% of Fundsmith LLP’s holdings, making the stock its 10th biggest holding. Fundsmith LLP owned about 3.25% of IDEXX Laboratories worth $1,100,931,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Sax Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 76.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company’s stock worth $590,000 after purchasing an additional 617 shares during the last quarter. Hantz Financial Services Inc. increased its stake in shares of IDEXX Laboratories by 11.5% during the fourth quarter. Hantz Financial Services Inc. now owns 7,738 shares of the company’s stock valued at $3,199,000 after buying an additional 800 shares during the period. Paragon Capital Management Inc. raised its holdings in shares of IDEXX Laboratories by 25.7% during the fourth quarter. Paragon Capital Management Inc. now owns 3,820 shares of the company’s stock valued at $1,579,000 after acquiring an additional 782 shares in the last quarter. Manitou Investment Management Ltd. lifted its stake in IDEXX Laboratories by 491.0% in the fourth quarter. Manitou Investment Management Ltd. now owns 52,202 shares of the company’s stock worth $21,582,000 after acquiring an additional 43,369 shares during the period. Finally, Fiera Capital Corp boosted its holdings in IDEXX Laboratories by 12.3% in the fourth quarter. Fiera Capital Corp now owns 141,198 shares of the company’s stock valued at $58,377,000 after acquiring an additional 15,463 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 12th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Bank of America raised their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. Stifel Nicolaus dropped their price target on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating on the stock in a research report on Monday, April 14th. Finally, Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a report on Monday. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and an average target price of $524.75.

Insider Buying and Selling

In other news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.98% of the stock is owned by corporate insiders.

IDEXX Laboratories Trading Up 0.7 %

NASDAQ IDXX opened at $489.98 on Friday. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $548.88. The stock’s fifty day moving average price is $422.31 and its 200-day moving average price is $429.15. The stock has a market cap of $39.71 billion, a P/E ratio of 45.92, a P/E/G ratio of 3.41 and a beta of 1.52. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analysts’ expectations of $998.25 million. IDEXX Laboratories had a net margin of 22.78% and a return on equity of 55.82%. The firm’s revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company earned $2.71 earnings per share. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.